Vor Biopharma/$VOR
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Vor Biopharma
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.
- Ticker
- $VOR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 76
- Headquarters
- Boston, United States
- Website
- www.vorbio.com
Vor Biopharma Metrics
BasicAdvanced
$1.2B
0.63
$30.51
1.78
-
Price and volume
Market cap
$1.2B
Beta
1.78
52-week high
$26.00
52-week low
$6.50
Average daily volume
758K
Financial strength
Current ratio
13.497
Quick ratio
13.25
Long term debt to equity
-0.018
Total debt to equity
-0.02
Profitability
EBITDA (TTM)
-147.584
Management effectiveness
Return on assets (TTM)
-27.45%
Return on equity (TTM)
-114.59%
Valuation
Price to earnings (TTM)
0.633
Price to book
-8.65
Price to tangible book (TTM)
-8.65
Price to free cash flow (TTM)
-7.162
Free cash flow yield (TTM)
-13.96%
Free cash flow per share (TTM)
-2.698
Growth
Earnings per share change (TTM)
-107.07%
3-year earnings per share growth (CAGR)
-6.65%
What the Analysts think about Vor Biopharma
Analyst ratings (Buy, Hold, Sell) for Vor Biopharma stock.
Analyst projections of the future price of Vor Biopharma stock.
Bulls say / Bears say
In the China Phase 3 TELIGAN study, telitacicept slowed kidney-function decline over two years: the annual eGFR slope was −0.6 versus −5.7 for placebo, with proteinuria reductions sustained through 104 weeks. This gives Vor encouraging clinical evidence in an additional autoimmune indication. (Vor Bio)
A China Phase 3 analysis in myasthenia gravis found that about 42% of treated participants achieved minimal symptom expression over 48 weeks, and most remained in that state at the next assessment. These results offer supportive evidence ahead of Vor’s global trial readout. (Vor Bio)
Vor has completed enrolment in its global Phase 3 trial for generalised myasthenia gravis, with results expected in the first half of 2027. It is also running a Phase 3 Sjögren’s disease trial and plans a Phase 3 ocular myasthenia gravis study, giving investors several development milestones to watch. (Vor Bio)
The encouraging myasthenia gravis results come from a China study, and experts have questioned whether its unusually low placebo response will carry over to global patients. Vor’s global Phase 3 result, due in the first half of 2027, must confirm the benefit in a broader setting. (NeurologyLive, Vor Bio)
Vor has no marketed product and expects ongoing losses; its latest filing says it will need substantial additional funding to support operations and development. Although current cash is expected to last into early 2029, further financing could dilute shareholders if trials do not lead to revenue. (SEC)
Vor will have to prove its treatment stands out in a competitive myasthenia gravis market. The company’s recent discussion covered established biologics such as efgartigimod and an emerging rival dual BAFF/APRIL drug, so telitacicept’s hoped-for differentiation is not yet assured. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 13 Nov 2026.
Vor Biopharma Financial Performance
Revenues and expenses
Vor Biopharma Earnings Performance
Company profitability
Upcoming events
No upcoming events
Vor Biopharma News
AllArticlesVideos
Funds containing Vor Biopharma
Fund name | Fund size | $VOR weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.3B | 0.07% |
iShares Nasdaq US Biotechnology$BTEC | $1.3B | 0.07% |
SPDR Russell 2000 US Small Cap€R2US | $4.7B | 0.03% |
SPDR Russell 2000 US Small Cap£R2SC | $4.7B | 0.03% |
Xtrackers MSCI World Small Cap$XSWC | $183M | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.